{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:29:31Z","timestamp":1781162971563,"version":"3.54.1"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Ceftazidime-avibactam is an effective agent for the treatment of tuberculosis (TB) but requires frequent administration because of a short half-life. Due to a longer half-life, ceftriaxone could allow intermittent dosing.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>First, we identified the MIC of ceftriaxone with 15\u2009mg\/L avibactam in 30 clinical <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic> isolates. Next, 2 ceftriaxone exposure-effect studies in the intracellular hollow fiber model of TB (HFS-TB) that mimics disseminated disease in young children, were performed. Ceftriaxone was administered once or twice daily for 28 days to explore percentage of time that the concentration persisted above MIC (%T<jats:sub>MIC<\/jats:sub>) ranging from 0 to 100%. In a third HFS-TB experiment, the \u201cdouble cephalosporin\u201d regimen of ceftazidime-ceftriaxone-avibactam was examined and analyzed using Bliss Independence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The MIC<jats:sub>99<\/jats:sub> of the clinical strains was 32\u2009mg\/L, in the presence of 15\u2009mg\/L avibactam. Ceftriaxone %T<jats:sub>MIC<\/jats:sub> &lt;42 had no microbial effect in the HFS-TB, %T<jats:sub>MIC<\/jats:sub>\n                                 <jats:italic toggle=\"yes\">&gt;<\/jats:italic>54% demonstrated a 4.1 log<jats:sub>10<\/jats:sub> colony-forming units per milliliter <jats:italic toggle=\"yes\">M. tuberculosis<\/jats:italic> kill, while %T<jats:sub>MIC<\/jats:sub> mediating E<jats:sub>max<\/jats:sub> was 68%. The \u201cdouble cephalosporin\u201d combination was highly synergistic. Monte Carlo experiments of 10,000 subjects identified the optimal ceftriaxone dose as 100\u2009mg\/kg twice a day.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The combination of ceftriaxone-avibactam at 100\u2009mg\/kg could achieve E<jats:sub>max<\/jats:sub> in &gt;90% of children. The ceftriaxone potent activity <jats:italic toggle=\"yes\">M. tuberculosis<\/jats:italic> could potentially shorten therapy in children with disseminated TB.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002857","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T10:01:43Z","timestamp":1597053703000},"page":"1092-1100","source":"Crossref","is-referenced-by-count":13,"title":["Evaluation of Ceftriaxone Plus Avibactam in an Intracellular Hollow Fiber Model of Tuberculosis: Implications for the Treatment of Disseminated and Meningeal Tuberculosis in Children"],"prefix":"10.1097","volume":"39","author":[{"given":"Shashikant","family":"Srivastava","sequence":"first","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center"},{"name":"Department of Immunology, UT Southwestern Medical Center, Dallas"},{"name":"Department of Pulmonary Immunology, University of Texas Health Centre, Tyler"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"van Zyl","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayle","family":"Cirrincione","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Martin","sequence":"additional","affiliation":[{"name":"Praedicare Laboratories, Praedicare, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Thomas","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devyani","family":"Deshpande","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-William","family":"Alffenaar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney, School of Pharmacy"},{"name":"Westmead Hospital"},{"name":"Marie Bashir Institute of Infectious Diseases, The University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Seddon","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Imperial College London, United Kingdom"},{"name":"Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center"},{"name":"Praedicare Laboratories, Praedicare, Dallas, Texas"},{"name":"Department of Medicine, University of Cape Town, Observatory, South Africa."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,8,10]]},"reference":[{"key":"R1-20230912","first-page":"30079\u201330076","article-title":"The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.","volume":"S2213-2600","author":"Dheda","year":"2017","journal-title":"Lancet Respir Med"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMp1314385","article-title":"FDA approval of bedaquiline \u2013 the benefit-risk balance for drug-resistant tuberculosis.","volume":"371","author":"Cox","year":"2014","journal-title":"N Engl J Med"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","article-title":"Delamanid for multidrug-resistant pulmonary tuberculosis.","volume":"366","author":"Gler","year":"2012","journal-title":"N Engl J Med"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMc1505196","article-title":"Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis.","volume":"373","author":"Bloemberg","year":"2015","journal-title":"N Engl J Med"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1164\/rccm.201502-0372LE","article-title":"Delamanid and bedaquiline resistance in Mycobacterium tuberculosis ancestral Beijing genotype causing extensively drug-resistant tuberculosis in a Tibetan refugee.","volume":"193","author":"Hoffmann","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"e102135","DOI":"10.1371\/journal.pone.0102135","article-title":"Acquired resistance of Mycobacterium tuberculosis to bedaquiline.","volume":"9","author":"Andries","year":"2014","journal-title":"PLoS One"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/cid\/cix992","article-title":"Bedaquiline resistance: its emergence, mechanism, and prevention.","volume":"66","author":"Nguyen","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijid.2014.12.031","article-title":"Repurposing \u2013 a ray of hope in tackling extensively drug resistance in tuberculosis.","volume":"32","author":"Maitra","year":"2015","journal-title":"Int J Infect Dis"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1093\/cid\/ciz334","article-title":"Acquired drug resistance: recognizing the potential of repurposed drugs.","volume":"69","author":"Alffenaar","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"e02232-e02217","DOI":"10.1128\/AAC.02232-17","article-title":"Antibacterial and sterilizing effect of benzylpenicillin in tuberculosis.","volume":"62","author":"Deshpande","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"e1701102","DOI":"10.1126\/sciadv.1701102","article-title":"Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.","volume":"3","author":"Deshpande","year":"2017","journal-title":"Sci Adv"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"34293","DOI":"10.1038\/srep34293","article-title":"Repurposing clinically approved cephalosporins for tuberculosis therapy.","volume":"6","author":"Ram\u00f3n-Garc\u00eda","year":"2016","journal-title":"Sci Rep"},{"issue":"Suppl 3","key":"R14-20230912","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1086\/651490","article-title":"Pediatric tuberculosis: global overview and challenges.","volume":"50","author":"Swaminathan","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/jcph.317","article-title":"Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis.","volume":"54","author":"Zhao","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/515003","article-title":"Antibiotic pharmacodynamics in cerebrospinal fluid.","volume":"27","author":"Lutsar","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"suppl 3","key":"R17-20230912","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/cid\/ciw471","article-title":"Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests.","volume":"63","author":"Swaminathan","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00749-10","article-title":"An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.","volume":"55","author":"Pasipanodya","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/infdis\/jiv068","article-title":"Fatal lure of look-back studies in explaining pharmacological events such as acquired drug resistance in patients with multidrug-resistant tuberculosis.","volume":"212","author":"Pasipanodya","year":"2015","journal-title":"J Infect Dis"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ebiom.2016.02.040","article-title":"A long-term co-perfused disseminated tuberculosis-3D liver hollow fiber model for both drug efficacy and hepatotoxicity in babies.","volume":"6","author":"Srivastava","year":"2016","journal-title":"EBioMedicine"},{"issue":"suppl 3","key":"R22-20230912","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/cid\/ciw474","article-title":"A faropenem, linezolid, and moxifloxacin regimen for both drug-susceptible and multidrug-resistant tuberculosis in children: FLAME path on the milky way.","volume":"63","author":"Deshpande","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1128\/AAC.23.2.191","article-title":"Pharmacokinetics of ceftriaxone in pediatric patients with meningitis.","volume":"23","author":"Steele","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"e1004603","DOI":"10.1371\/journal.ppat.1004603","article-title":"Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization.","volume":"11","author":"Gideon","year":"2015","journal-title":"PLoS Pathog"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly.","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann Appl Biol"},{"key":"R28-20230912","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3389\/fphar.2017.00158","article-title":"An introduction to terminology and methodology of chemical synergy-perspectives from across disciplines.","volume":"8","author":"Roell","year":"2017","journal-title":"Front Pharmacol"},{"issue":"Suppl 6","key":"R29-20230912","doi-asserted-by":"crossref","first-page":"S635","DOI":"10.1093\/cid\/civ715","article-title":"Single or 2-dose micafungin regimen for treatment of invasive candidiasis: therapia sterilisans magna!.","volume":"61","author":"Gumbo","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1086\/424849","article-title":"Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.","volume":"190","author":"Gumbo","year":"2004","journal-title":"J Infect Dis"},{"key":"R31-20230912","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/01621459.1949.10483310","article-title":"The Monte Carlo method.","volume":"44","author":"Metropolis","year":"1949","journal-title":"J Am Stat Assoc"},{"key":"R32-20230912","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0022-3476(84)80032-3","article-title":"Pharmacokinetics of ceftriaxone in neonates and infants with meningitis.","volume":"105","author":"Martin","year":"1984","journal-title":"J Pediatr"},{"key":"R33-20230912","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ijantimicag.2010.01.001","article-title":"Free concentration and protein-binding ratio of ceftriaxone in cerebrospinal fluid in paediatric patients with purulent meningitis caused by Haemophilus influenzae type b.","volume":"35","author":"Hoshino","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"R34-20230912","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/510079","article-title":"Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it\u2019s not just for mice anymore.","volume":"44","author":"Ambrose","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R35-20230912","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1128\/AAC.00320-06","article-title":"Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics.","volume":"50","author":"Wang","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R36-20230912","first-page":"1081","article-title":"Inhibition of \u03b2-lactamases of mycobacteria by avibactam and clavulanate.","volume":"72","author":"Soroka","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R37-20230912","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/adc.2003.044156","article-title":"Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children.","volume":"89","author":"Avci","year":"2004","journal-title":"Arch Dis Child"},{"key":"R38-20230912","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1128\/AAC.50.5.1869-1871.2006","article-title":"Pharmacokinetics of a new, orally available ceftriaxone formulation in physical complexation with a cationic analogue of bile acid in rats.","volume":"50","author":"Lee","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R39-20230912","doi-asserted-by":"crossref","first-page":"10340","DOI":"10.1021\/acs.jmedchem.8b01389","article-title":"Orally absorbed derivatives of the \u03b2-lactamase inhibitor avibactam. design of novel prodrugs of sulfate containing drugs.","volume":"61","author":"Gordon","year":"2018","journal-title":"J Med Chem"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002857","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:59:11Z","timestamp":1694559551000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,10]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002857","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,10]]}}}